New Directions in the Frontline Treatment of DLBCL: Implications for Practice

New Directions in the Frontline Treatment of DLBCL: Implications for Practice New Directions in the Frontline Treatment of DLBCL: Implications for Practice
CME, CPE
James O. Armitage, MD; and Andrew D. Zelenetz, MD, PhD
 
Release Date: November 09, 2022
Expiration Date: November 09, 2023

In this activity, Dr. Zelenetz will address current and emerging approaches in the frontline treatment of diffuse large b-cell lymphoma (DLBCL), he will also discuss current and potential practice implications. To conclude, Dr. Armitage and Dr. Zelenetz discuss how to apply these therapies to practice and look to future changes which may impact overall patient outcomes.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol Myers Squibb and Genentech, a member of the Roche Group.
Begin, Earn CreditView Only, No Credit
 

© 2022 MediCom Worldwide, Inc. All rights reserved